asthma medicines
-
Valeo Pharma Impresses Again with 210% Quarterly Year-over-Year Revenue Growth
Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) (“Valeo”) just released their FQ1/2023 earnings results and impressed again.…
-
Valeo Pharma’s CEO Steve Saviuk Talks about Record FQ4 & F2022 Revenue Up 274% & 105%, Respectively
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO,…
-
Steve Saviuk on how Valeo Pharma’s ‘life changing’ products have delivered the strong growth forecasted for 2022
In this InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and…
-
Valeo Pharma keeps delivering with a 100% revenue growth forecast in 2022 and more new effective pharmaceuticals
Early in 2022 InvestorIntel updated readers about a company that was growing its revenue at an incredible rate…
